Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
European heart journal. Cardiovascular pharmacotherapy, 2026
Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study
The Laryngoscope, 2026
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness
JAMA psychiatry, 2026
GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far
Current oncology reports, 2026;28(1)
Inappropriate use of GLP-1-based antiobesity medications: beyond appropriate drug use toward appropriate weight reduction
Diabetology international, 2026;17(4):71
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Cardiovascular diabetology, 2026;25(1)
Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study
Science progress, 2026;109(3):368504261484176
Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2026;1283:125267
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis
Cureus, 2026;18(8):e115260
Social Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis
JMIR diabetes, 2026;11:e87590
Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study
Journal of medical Internet research, 2026;28:e80119
Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery – a systematic review and meta-analysis
Frontiers in endocrinology, 2026;17:1870008
Electroacupuncture enables semaglutide dose sparing in type 2 diabetes by boosting drug concentration and suppressing β-cell apoptosis
Frontiers in endocrinology, 2026;17:1880819
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
The American journal of managed care;32(7):392-395
Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide
Obesity facts, 2026;:1-23
Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease
Clinical journal of the American Society of Nephrology : CJASN, 2026
Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network
Pulmonology, 2026;32(1):2722795
A microencapsulation strategy for intranasal semaglutide delivery
Journal of microencapsulation, 2026;:1-11
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation
Diabetes, obesity & metabolism, 2026
Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society
Maturitas, 2026;213:109101